Nevirapine-associated Stevens-Johnson syndrome [1]

Lancet

Volumn 351, Issue 9102, 1998, Pages 567-

  Warren, Kelly J ^b   Boxwell, Debra E ^b   Kim, Nancy Y ^b   Drolet, Beth A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ADULT; CASE REPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME;

EID: 0032554284     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24008-6     Document Type: Article

References (5)

1. 1 Bayard PJ, Berger TG, Jacobsen MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992; 5: 237-57.
2. 2 Caumes E, Saiag P, Picard C, et al. Sulfonamide-induced toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) in AIDS patients: 12 cases. Presented at 1988 Fourth International Conference on AIDS, Stockholm, Sweden, June 15-16, 1988.
3. 3 Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. Clin Infect Dis 1995; 23: 640-41.
4. 4 Carr A, Vella S, DeJohn MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996; 10: 635-41.
5. 5 D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 1019-30.